General Information of Drug (ID: DM9YNTO)

Drug Name
ERY974 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM9YNTO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Glypican-3 (GPC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
RG7686 DM6CNFW Hepatocellular carcinoma 2C12.02 Phase 2 [3]
GPC-3298306 DMOHAS2 Hepatocellular carcinoma 2C12.02 Phase 2 [4]
Codrituzumab DMDWG36 Hepatic metastasis 2D80 Phase 2 [2]
GC33 DMXTD74 Hepatocellular carcinoma 2C12.02 Phase 2 [3]
SAR444200 DM7J5H0 Aggressive cancer 2A00-2F9Z Phase 2 [5]
GPC3-CART cells DMGN679 Hepatocellular carcinoma 2C12.02 Phase 1/2 [6]
TAI-GPC3-CART cells DMCFSZ5 Hepatocellular carcinoma 2C12.02 Phase 1/2 [7]
CAR-T cells targeting GPC3 DM6H1MQ Hepatocellular carcinoma 2C12.02 Phase 1/2 [8]
Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs DMDO6J1 Hepatocellular carcinoma 2C12.02 Phase 1/2 [9]
CAR-T cells targeting Glypican-3 (GPC3) DMDSKR2 Hepatocellular carcinoma 2C12.02 Phase 1/2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glypican-3 (GPC3) TTJTSX4 GPC3_HUMAN Inhibitor [2]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.
4 Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi. 2008 Oct;31(5):383-91.
5 Clinical pipeline report, company report or official report of Sanofi
6 ClinicalTrials.gov (NCT03130712) A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)
7 ClinicalTrials.gov (NCT02715362) A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
8 ClinicalTrials.gov (NCT02959151) A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy
9 ClinicalTrials.gov (NCT03084380) Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
10 ClinicalTrials.gov (NCT02723942) CAR-T Cell Immunotherapy for HCC Targeting GPC3